Summary
Adozelesin (U-73975) is a potent synthetic cyclopropylpyrroloindole (CPI) analog of the cytotoxic DNA-binding antibiotic, CC-1065. In contrast to the natural product, adozelesin and related CPI analogs do not cause delayed death in non-tumored mice. Adozelesin, selected from a series of analogs for its superior in vivo antitumor activity and ease of formulation, is highly active when administered i.v. against i.p.- or s.c.-implanted murine tumors, including L1210 leukemia, B16 melanoma, M5076 sarcoma, and colon 38 carcinoma, and produces long-term survivors in mice bearing i.v.-inoculated L1210 and Lewis lung carcinoma. Modest activity is shown against the highly drug-resistant pancreas 02 carcinoma. Adozelesin is also highly effective against human tumor xenografts s.c.-implanted in athymic (nude) mice, including colon CX-1 adenocarcinoma, lung LX-1 tumor, clear cell Caki-1 carcinoma, and ovarian 2780 carcinoma. Its broad spectrum of in vivo activity compares favorably with three widely used antitumor drugs, i.e. cisplatin, cyclophosphamide, and doxorubicin. Adozelesin appears to be more effective than these drugs in the treatment of very resistant tumors such as s.c.-implanted mouse B16 melanoma, pancreatic 02 carcinoma, and human colon CX-1 and human lung LX-1 tumor xenografts. Based on its high potency and high efficacy against a broad spectrum of experimental tumors, adozelesin was chosen for clinical investigation and development.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hanka LJ, Dietz A, Gerpheide SA, Kuentzel SL, Martin DG: CC-1065 (NSC 298223), a new antitumor antibiotic. Production, in vitro biological activity, microbiological assays and taxonomy of the producing microorganism. J Antibiot 31:1211–1217, 1978
Martin DG, Chidester CG, Duchamp DJ, Mizsak SA: Structure of CC-1065 (NSC 298223), a new antitumor antibiotic. J Antibiot 33:902–903, 1980
Li LH, Swenson DH, Schpok SL, Kuentzel SL, Dayton BD, Krueger WC: CC-1065 (NSC 298223), a novel antitumor agent that interacts strongly with double-stranded DNA. Cancer Res 42:999–1004, 1982
Swenson DH, Li LH, Hurley LH, Rokem JS, Petzold GL, Dayton BD, Wallace TL, Lin AH, Krueger WK: Mechanism of interaction of CC-1065 (NSC 298223) with DNA. Cancer Res 42:2821–2828, 1982
Hurley LH, Reynolds VL, Swenson DH, Petzold GL, Scahill TA: Reaction of the antitumor antibiotic CC-1065 with DNA: Structure of a DNA adduct with DNA sequence specificity. Science 226:843–844, 1984
Martin DG, Biles C, Gerpheide SA, Hanka LJ, Krueger WC, McGovren JP, Mizsak SA, Neil GL, Stewart JC, Visser J: CC-1065 (NSC 298223), a potent new anti-tumor agent. Improved production and isolation, characterization and antitumor activity. J Antibiot 34:1119–1125, 1981
McGovren JP, Clarke GL, Pratt EA, DeKoning TF: Preliminary toxicity studies with the DNA-binding antibiotic, CC-1065. J Antibiot 37:63–70, 1984
Wierenga W: Synthesis of the left-hand segment of the antitumor agent CC-1065. J Am Chem Soc 103:5621–5623, 1981
Warpehoski MA: Total synthesis of U-71,184, a potent new antitumor agent modeled on CC-1065. Tet Letters 27:4103–4106, 1986
Kelly RC, Gehbard I, Wicnienski N, Aristoff PA, Johnson PD, Martin DG: Coupling of cyclopropapyrroloindole (CPI) derivatives. The preparation of CC-1065, entCC-1065, and analogs. J Am Chem Soc 109:6837–6838, 1987
Warpehoski MA, Gebhard I, Kelly RC, Krueger WC, Li LH, McGovren JP, Prairie MP, Wicnienski N, Wierenga W: Stereoelectronic factors influencing the biological activity and DNA interaction of synthetic antitumor agents modeled on CC-1065. J Med Chem 31:590–603, 1988
Wierenga W, Bhuyan BK, Kelly RC, Krueger WC, Li LH, McGovren JP, Swenson DH, Warpehoski MA: Antitumor activity and biochemistry of novel analogs of the antibiotic, CC-1065. Adv Enzyme Regul 25:141–155, 1986
Li LH, Wallace TL, DeKoning TF, Warpehoski MA, Kelly RC, Prairie MD, Krueger WC: Structure and activity relationship of several novel CC-1065 analogs. Invest New Drugs 5:329–337, 1987
Hurley LH, Lee CS, McGovren JP, Warpehoski MA, Mitchell MA, Kelly RC, Aristoff PA: Molecular basis for sequence-specific DNA alkylation by CC-1065. Biochem 27:3886–3892, 1988
Warpehoski MA, Bradford VS: Bis-des-hydroxy, bis-desmethoxy CC-1065. Synthesis, DNA binding, and biological activity. Tet Letters 29:131–134, 1988
U.S. National Cancer Institute: In vivo cancer models. NIH publication No. 84-2635, 1984
Goldin A, Yenditti JM, Carter SK: Screening at the National Cancer Institute. In: Saunders JF, Carter SK, eds. Methods of development of new anticancer drugs. Natl Cancer Inst Monograph 45:37–48, 1977
Giovanella BC, Shepard RC, Stehlin JS, Venditti JM, Abbott BJ: Calorie restriction: Effect on growth of human tumors heterotransplanted in nude mice. J Natl Cancer Inst 68:249–257, 1982
Corbett TH, Roberts BJ, Leopold WR, Peckham JC, Wilkoff LJ, Griswold Jr, DP, Schabel Jr, FM: Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res 44:717–726, 1984
Pratt WB, Ruddon RW: The anticancer drugs. Oxford, U.K.: Oxford Univ Press, pp 64–88 and 251–255, 1982
Fisher JF, Aristoff PA: The chemistry of DNA modification by antitumor antibiotics. Prog Drug Res 32:411–498, 1988
Goldin A, Venditti JM, MacDonald JS, Muggia FM, Henney JE, Devita Jr. VT: Current results of the screening program at the Division of Cancer Treatment, National Cancer Inst. Europ J Canc 17:129–142, 1981
Staquet MJ, Byar DP, Green SB, Rozenweig M: Clinical predictivity of transplantable tumor systems in the selection of new drugs for solid tumors: Rationale for a three-stage strategy. Cancer Treat Rep 67:753–765, 1983
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Li, L.H., Kelly, R.C., Warpehoski, M.A. et al. Adozelesin, a selected lead among cyclopropylpyrroloindole analogs of the DNA-binding antibiotic, CC-1065. Invest New Drugs 9, 137–148 (1991). https://doi.org/10.1007/BF00175081
Issue Date:
DOI: https://doi.org/10.1007/BF00175081